ClinicalTrials.gg
CompletedNCT03355196Updated Dec 11, 2020

First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients

A Phase 1 interventional study of LRX712 and Placebo in Patients With Moderate Knee Osteoarthritis (30 - 65 Years), sponsored by Novartis Pharmaceuticals. Completed at 1 site in Netherlands. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Osteoarthritis, Knee by Novartis — none open to participants now, none under way, none of them phase 3. Osteoarthritis, Knee · Novartis.

Enrollment
13th of 14
42 · median 264
Started
2017
the only one that year
Phase 1
Only one
of the 14
Registered
9th of 14
by date

Among the 14 studies in Osteoarthritis, Knee by Novartis, this one is the 13th largest by enrollment, is the only one that started in 2017, is the only one in phase 1, and was the 9th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

None of the 14 studies in Osteoarthritis, Knee by Novartis is open now. The open studies under Osteoarthritis, Knee, anywhere →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Osteoarthritis, Knee by Novartis as a file.
02

Study summary

This study is designed to evaluate, for the first time in humans, safety and tolerability of single ascending doses of intra-articular (i.a.) injections of LRX712 into the knee of patients with moderate osteoarthritis (OA), in order to support the further clinical development. This study will also allow establishment of the systemic and local pharmacokinetics (PK) of LRX712 and the exploration of biomarkers of cartilage breakdown and regeneration in OA patients.

03

Conditions studied

  • Patients With Moderate Knee Osteoarthritis (30 - 65 Years)

Keywords

  • Osteoarthritic patients
  • Cartilage
  • Safety
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients, 30 to 65 years of age inclusive, and in good health as determined by medical history, physical examination, vital signs, , and laboratory tests at screening.
  • At screening, and at baseline vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three minutes, and again (when required) after three minutes in the standing position as outlined in the SOM.

Sitting vital signs should be guided by the following ranges:

  • body temperature between 35.0-37.5 °C
  • systolic blood pressure 90-139 mm Hg
  • diastolic blood pressure 50-89 mm Hg
  • pulse rate, 40 - 90 bpm • Subjects must weigh at least 50 kg to participate in the study, and must have a (BMI) within the range of 18 - 32 kg/m2. BMI = Body weight (kg) / [Height (m)]

Exclusion criteria

Exclusion Criteria:

  • Women of , defined as all women physiologically capable of becoming pregnant.
  • Pregnant or nursing (lactating) women
  • Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
  • A history of abnormalities, or any of the following ECG abnormalities at screening and baseline

    • PR > 200 msec
    • QRS complex > 120 msec
    • > 450 msec (males)
    • QTcF > 460 msec (females)
  • Known family history or known presence of long QT syndrome
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    LRX712

    LRX712 given intra-articularly

    Drug: LRX712

  • Placebo comparator
    Placebo

    Placebo given intra-articularly

    Drug: Placebo

Interventions

  • DrugLRX712

    Ascending single dose on Day 1

  • DrugPlacebo

    Ascending single dose on Day 1

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single intra-articular (i.a.) injection in Osteoarthritic (OA) patients

    To evaluate Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of LRX712 after a single i.a. injection in osteoarthritic patients

    Time frame: Day 29

Secondary outcomes

  1. Time to Reach the Maximum Plasma Concentration (Tmax)

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Time to Reach the Maximum Plasma Concentration (Tmax)

    Time frame: pre-dose to 29 days post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Maximum Observed Plasma Concentration (Cmax)

    Time frame: pre-dose to 29 days post-dose

  3. Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)

    Time frame: pre-dose to 29 days post-dose

  4. Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    Time frame: pre-dose to 29 days post-dose

  5. Half-life (T1/2)

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Half-life (T1/2)

    Time frame: pre-dose to 29 days post-dose

  6. CL/F - Total clearance

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - CL/F - Total clearance

    Time frame: pre-dose to 29 days post-dose

  7. Vz/F - Volume of Distribution

    To evaluate LRX712 and metabolite MAE344 pharmacokinetics in plasma - Vz/F - Volume of Distribution

    Time frame: pre-dose to 29 days post-dose

07

Study locations

1 site
  • Novartis Investigative Site
    Leiden, 2333 CL, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2019, 16 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 16 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 28, 2017
StartActual
Nov 20, 2017
Primary completionActual
Mar 26, 2019
CompletionActual
Mar 26, 2019
Last update
Dec 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03355196
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Nov 20, 2017
Primary completion
Mar 26, 2019
Completion
Mar 26, 2019
Last update
Dec 11, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion